ERBB2 and neoplasm: Selected biomarkers with a positive association with pCR included homogeneous HER2 IHC3+ intensity; HER2 mRNA expression > median by both qRT-PCR and Nanostring; HER2 H-score ≥ median; HER2 gene ratio ≥ 4; PAM50 HER2-E subtype; PD-L1-positive IHC status; stromal TILs > 10%; tumor mass TILs > 10%; and immune gene signatures, epidermal growth factor receptor (EGFR), MDR1/ABCB1, and MET gene expression > median.